Public Release: 

Eye drops delay onset of glaucoma in people at higher risk

NIH/National Eye Institute



A scene as it might be viewed by a person with glaucoma. (Credit: National Eye Institute, National Institutes of Health)

Full size image available through contact

Researchers have discovered that eye drops used to treat elevated pressure inside the eye can be effective in delaying the onset of glaucoma. These results mean that treating people at higher risk for developing glaucoma may delay -- and possibly prevent -- the disease. These findings are reported in the June 2002 issue of Archives of Ophthalmology.

Scientists found that pressure-lowering eye drops reduced by more than 50 percent the development of primary open-angle glaucoma, the most common form of glaucoma and one of the nation's leading causes of vision loss. Researchers noted that 4.4 percent of the study participants who received the eye drops developed glaucoma within five years. By comparison, 9.5 percent of the study participants who did not receive the eye drops developed glaucoma. Additionally, several significant risk factors were found to be associated with the development of glaucoma in study participants. These included personal risk factors, such as older age and African descent, as well as ocular risk factors, such as higher eye pressure, certain characteristics in the anatomy of the optic nerve, and thinness of the cornea.

Elevated eye pressure results when the fluid that flows in and out of the eye drains too slowly, gradually increasing pressure inside the eye. It is estimated that between three and six million people in the U.S. -- including between four and seven percent of the population above age 40 -- have elevated eye pressure and are at increased risk for developing open-angle glaucoma. Until now, doctors did not know if treating elevated eye pressure -- before glaucoma developed -- could delay the onset of the disease. Some doctors treat people with elevated eye pressure, others do not. This study provides some important information to consider in reaching a decision about treatment.

"This study showed that treating elevated eye pressure delays or prevents the onset of glaucoma in some people," said Paul A. Sieving, M.D., Ph.D., director of the National Eye Institute (NEI), a component of the Federal government's National Institutes of Health (NIH) and one of the study's sponsors. "The study clearly makes a connection between elevated eye pressure and the onset of glaucoma. However, not all people with elevated eye pressure should be treated with the eye drops. If you are at risk for glaucoma, see your eye care professional to receive a comprehensive eye exam and find out if eye drops might help."

The study -- called the Ocular Hypertension Treatment Study -- examined 1636 people 40-80 years of age who had elevated eye pressure but no signs of glaucoma. Half were assigned daily eye drops, and the other half were assigned to observation (no medication). In the medication group, treatment reduced eye pressure by approximately 20 percent.

"It is significant that this modest 20 percent reduction in eye pressure had such an important protective effect in the development of glaucoma," said Michael Kass, M.D., of the Washington University Department of Ophthalmology and Visual Sciences and chair of the study.

Dr. Kass sounded a cautionary note. "Eye care professionals should not prescribe eye drops for all people who have elevated eye pressure with no sign of glaucoma," he said. "Doctors should take into account several factors, including the simple fact that 90 percent of participants in the observation group did not develop glaucoma within the five-year study period. An individual's risk of developing glaucoma, along with their health status and life expectancy, should be considered. The burden of daily treatment, including cost, inconvenience, and possible side effects, are other factors that the doctor and patient should discuss." Dr. Kass said that study researchers prescribed commercially available eye drops, either singly or in combination, to reduce eye pressure. "The availability of many different types of pressure-lowering eye drops allows eye care professionals to choose the safest regimen for each patient," he said. In the study, the group receiving the eye drops did not show increased evidence of health problems in comparison to the observation group.

Open-angle glaucoma affects about 2.2 million Americans age 40 and over; another two million may have the disease and don't know it. Glaucoma occurs when the optic nerve is damaged. In most cases, increased pressure in the eye plays an important role in this damage. The damage to the optic nerve causes loss of peripheral (side) vision. As the disease worsens, the field of vision gradually narrows and blindness can result. However, if detected early through a comprehensive eye exam, glaucoma can usually be controlled and serious vision loss prevented. Comprehensive eye examinations are recommended for all people over age 60, and African Americans over age 40.

Glaucoma is the leading cause of blindness in African Americans, according to John Ruffin Ph.D., director of the National Center on Minority Health and Health Disparities (NCMHD), part of NIH and another study sponsor. "Glaucoma is three to four times more likely to develop in African Americans than Whites," Dr. Ruffin said. "This study took that into account: 25 percent of study participants were African American."

Dr. Sieving said this clinical trial is among the studies supported in the National Eye Institute's glaucoma research program. "We will continue to conduct and support research aimed at finding better ways to detect, treat, and possibly prevent glaucoma," he said.

In addition to support from the NEI and NCMHD, the Ocular Hypertension Treatment Study was supported by Research to Prevent Blindness and Merck Research Laboratories. The study was conducted at 22 clinical centers across the country. A list of study centers and principal investigators is attached.

The National Eye Institute (NEI), the Federal government's lead agency for vision research, is part of the National Institutes of Health (NIH) under the U.S. Department of Health and Human Services. NEI-supported research leads to sight-saving treatments and plays a key role in reducing visual impairment and blindness.

The NIH's National Center on Minority Health and Health Disparities (NCMHD) conducts and supports research, training, information dissemination and other programs aimed at reducing the disproportionately high incidence and prevalence of disease, burden of illness, and mortality experienced by certain American populations, including racial and ethnic minorities and other groups with disparate health status, such as the urban and rural poor.

Background
The Ocular Hypertension Treatment Study

Glaucoma is a group of diseases that can lead to damage to the eye's optic nerve and result in blindness. Open-angle glaucoma, the most common form of glaucoma, is one of the leading causes of blindness in the United States and the number one cause of blindness among African Americans. Glaucoma usually has no early symptoms, and by the time people experience problems with their vision, they usually have lost a significant amount of their sight.

How Open-Angle Glaucoma Develops

Increased pressure inside the eye is an important cause of open-angle glaucoma. In the front of the eye is a space called the anterior chamber. A clear fluid flows continuously in and out of this space and nourishes nearby tissues. The fluid leaves the anterior chamber at the angle where the cornea and iris meet. When the fluid reaches the angle, it flows through a spongy meshwork, like a drain, and leaves the eye.

Open-angle glaucoma gets its name because the angle that allows fluid to drain out of the anterior chamber is open. However, for unknown reasons, the fluid passes too slowly through the meshwork drain. As the fluid builds up, the pressure inside the eye rises. Elevated eye pressure can damage the optic nerve; a healthy optic nerve is necessary for good vision. When the optic nerve is damaged from increased pressure, glaucoma -- and vision loss -- are the result.

At first, open-angle glaucoma has no symptoms. People are not aware that glaucoma is affecting their vision, and there is no pain. When glaucoma remains untreated, people may notice that although they see things clearly in front of them, they miss objects to the side and out of the corner of their eye. Without treatment, people with glaucoma may find that they have no side vision. Over time, the remaining vision may decrease until there is no vision left.

The Ocular Hypertension Treatment Study

Prior to the Ocular Hypertension Treatment Study, there was no clear evidence as to whether reducing elevated pressure in the eye would delay or prevent the onset of glaucoma. Elevated pressure in the eye, a common condition affecting three to six million people in the United States, is thought to be the leading risk factor for development of open-angle glaucoma. For the purposes of this study, ocular hypertension -- which can be diagnosed by an eye care professional -- was defined as pressure of 24 mm Hg or greater in at least one eye.

Despite the lack of convincing evidence, approximately 1.5 million people in the U.S. with elevated eye pressure and no glaucoma damage are being treated with medications that lower this pressure. There was a need for a well-controlled clinical trial to determine whether medical reduction of elevated intraocular pressure could delay or prevent the onset of glaucoma. The resulting data would enable clinicians and patients to make rational choices and health care planners ensure that medical resources were being allocated in a safe and cost-effective manner.

The primary goal of the Ocular Hypertension Treatment Study was to determine whether reducing elevated eye pressure delayed or prevented the onset of glaucoma and subsequent vision loss in people at risk of developing the disease. Patient recruitment took place between February 28, 1994 and October 31, 1996. A total of 1636 individuals were selected to participate; 817 were assigned to receive topical ocular medication (eye drops), and 819 were assigned to observation. All of the medications used in the study were commercially available.

Scientists found that eye drops used to reduce pressure inside the eye were effective in delaying the onset of primary open-angle glaucoma. After five years, researchers found that treatment reduced the onset of primary open angle glaucoma by more than 50 percent.

The Ocular Hypertension Treatment Study is the first large-scale study to demonstrate that lowering eye pressure -- a risk factor for the development of primary open-angle glaucoma -- can safely and effectively delay and possibly prevent the disease.

High Risk Factors for Glaucoma

In a companion paper, also published in the June 2002 issue of Archives of Ophthalmology, the authors report finding several factors predictive of those who developed primary open angle glaucoma. These included personal risk factors, such as older age and African descent, as well as ocular risk factors, such as higher eye pressure, certain characteristics in the anatomy of the optic nerve, and thinness of the cornea. The authors note that "corneal thickness provides new information about the risk of developing primary open-angle glaucoma and we recommend its measurement in the clinical evaluation of patients with ocular hypertension."

The authors also point out that the predictive factors for glaucoma, as identified in the Ocular Hypertension Treatment Study, "are most likely to be helpful for assessing the risk of patients who resemble the study participants, i.e. ocular hypertensive individuals with eye pressure between 24 and 32 mm Hg and no evidence of glaucoma damage." Only about two percent of Americans have these high levels of pressure in at least one eye.

The authors conclude by saying that the study results "suggest that a clinician caring for an ocular hypertensive patient can assess that individual's risk" for developing glaucoma by considering age, race, eye pressure, optic nerve anatomy, and central corneal thickness. By considering these factors, "the clinician can identify patients who are at moderate to high risk for developing [glaucoma] and who are more likely to benefit from early medical treatment," the authors state.

###

Ocular Hypertension Treatment Study
Current Principal Investigators & Study Centers

California
Anne L. Coleman, M.D., Ph.D.
Jules Stein Eye Institute, UCLA
Los Angeles
(Satellite Office)
Richard S. Baker, M.D.
Charles R. Drew University
Los Angeles

James D. Brandt, M.D.
University of California, Davis
Sacramento

Robert N. Weinreb, M.D.
University of California, San Diego
La Jolla

Michael V. Drake, M.D.
University of California, San Francisco
San Francisco

District of Columbia
Douglas E. Gaasterland, M.D.
University of Ophthalmic Consultants of
Washington
(Satellite Offices)
Frank S. Ashburn, M.D.
Eye Associates of Washington, D.C.

Arthur Schwartz, M.D
Washington Eye Physicians and Surgeons

Howard Weiss, M.D.
Washington Hospital Center Eye Clinic

Florida
Donald Budenz, M.D.
Bascom Palmer Eye Institute
University of Miami School of Medicine
Miami

Georgia
Thomas S. Harbin, Jr., M.D.
Eye Consultants of Atlanta
Atlanta
(Satellite Office)
Paul McManus, M.D.
Eye Physicians and Surgeons
Decatur

Allen D. Beck, M.D.
Emory University Eye Center
Atlanta

Kentucky
Joern B. Soltau, M.D.
University of Louisville
Louisville

Maryland
Donald J. Zack, M.D., Ph.D.
The Johns Hopkins University School of
Medicine
Baltimore
(Satellite Offices)
Irvin Pollack, M.D.
Krieger Eye Institute
Baltimore

Alan L. Robin, M.D.
Baltimore

Robert A. Copeland, M.D.
Howard University
Washington, DC

Eve J. Higginbotham, M.D.
University of Maryland
Maryland Center for Eye Care
Baltimore

Michigan
G. Robert Lesser, M.D.
Henry Ford Medical Center
Detroit
(Satellite Offices)
Deborah Darnley-Fisch, M.D.
Henry Ford Medical Center
Dearborn

Naumann R. Imami, M.D.
Henry Ford Medical Center
Troy

Terry J. Bergstrom, M.D.
University of Michigan
W.K. Kellogg Eye Center
Ann Arbor

Bret A. Hughes, M.D.
Kresge Eye Institute
Wayne State University
Detroit
(Satellite Office)
John M. O'Grady, M.D.
Great Lakes Ophthalmology
Saginaw

Minnesota
David C. Herman, M.D.
Mayo Clinic/Foundation
Rochester
(Satellite Office)
Paul Kalina, M.D.
Mayo Clinic Foundation
Scottsdale, Arizona

Missouri
Martin B. Wax, M.D.
Washington University School of Medicine
St. Louis

New York
Jeffrey M. Liebmann, M.D.
The New York Eye and Ear Infirmary
New York

Ohio
Paul A. Weber, M.D.
Ohio State University
Columbus
(Satellite Office)
N. Douglas Baker, M.D.
Opthalmic Surgeons and Consultants
Columbus

Kathleen A. Lamping, M.D.
University Suburban Health Center
South Euclid

Oregon
George A. Cioffi, M.D.
Devers Eye Institute
Legacy Portland Hospitals
Portland

Pennsylvania
G. Richard Bennett, M.S., O.D.
Pennsylvania College of Optometry
Philadelphia

(Satellite Office)
Elliott Werner, M.D.
MCP/Hahnemann University
Philadelphia
Jody R. Piltz-Seymour, M.D.
Scheie Eye Institute
University of Pennsylvania
Philadelphia

Texas
Ronald L. Gross, M.D.
Cullen Eye Institute
Baylor College of Medicine
Houston

Resource Centers
Ocular Hypertension Treatment StudyWeb Site
http://www.ohts.wustl.edu

Study Chairman
Michael A. Kass, M.D.
Washington University
Dept. of Ophthalmology &Visual Sciences
660 South Euclid, Campus Box 8096
St. Louis, MO 63110
Telephone: (314) 362-5713

Vice Chairs
Dale K. Heuer, M.D.
Medical College of Wisconsin
Department of Ophthalmology
925 North 87th Street
Milwaukee, WI 53226-4812
Telephone: (414) 456-7915

Eve J. Higginbotham, M.D.
Maryland Center for Eye Care
Department of Ophthalmology
419 West Redwood, Room 580
Baltimore, M.D. 21201
Telephone: (410) 328-5929

Richard K. Parrish, II, M.D.
University of Miami
McKnight Vision Research Center - 5th Floor
1638 NW 10th Avenue
Miami, FL 33136
Telephone: (305) 326-6389
Coordinating Center
Mae O. Gordon, Ph.D.
Washington University
Dept. of Ophthalmology &Visual Sciences
Division of Biostatistics
660 South Euclid, Campus Box 8203
St. Louis, MO 63110
Telephone: (314) 362-3716

Visual Field Reading Center
John L. Keltner, M.D.
University of California, Davis
Department of Ophthalmology
4860 Y Street, Suite 2400
Sacramento, CA 95817
Telephone: (916) 734-6073

Chris A. Johnson, Ph.D.
Discoveries in Sight
1225 NE 2nd Avenue, 3rd Floor
Portland, OR 97232
Telephone: (503) 413-5318

Optic Disc Reading Center
Richard K. Parrish, II, M.D.
University of Miami
McKnight Vision Research Center - 5th Floor
1638 NW 10th Avenue
Miami, FL 33136-1015
Telephone: (305) 326-6385

NEI Representative
Donald F. Everett, M.A.
National Eye Institute
National Institutes of Health
Executive Plaza South, Suite 350
6120 Executive Boulevard
Bethesda, M.D. 20892
Telephone: (301) 451-2020

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.